Company profile
Hypha Discovery - Experts in metabolite synthesis, purification and MetID
Hypha Discovery is a trusted CRO with expertise in metabolite synthesis, purification, structure elucidation and natural products.
Reference milestones and recent Companies House filing stream events.
Next accounts due date
Next confirmation statement due date
CS01 | Transaction MzUyNTg0NDY1MmFkaXF6a2N4
Published 08 Jun 2026 07:20
Last accounts made up date
Last confirmation statement made up date
Company registered at Companies House
1 Jun 2020 to 30 Nov 2020
no public description
1 Apr 2019 to 31 Dec 2020
"Metabolites of drugs often need to be investigated and tested as part of regulated safety assessments during drug development. _N_-glucuronides are a class of metabolites increasingly observed as a significant route of drug elimination and are most likely to exhibit transporter-mediated pharmacologic activity and drug-drug-interactions. However, _N_-gluc...
1 Jul 2017 to 30 Sep 2019
The major healthcare imperatives are to deliver effective prevention and treatment of diseases. Whist pharmaceutical intervention in disease progress is effective in many cases, the use of medicines can also lead to adverse reactions resulting in the need for further medical intervention, compounding the cost of therapy. The aim of this project is to furt...
1 Jan 2016 to 31 Dec 2016
Microorganisms and their cytochrome P450 (CYP) oxidative enzymes can be used for production of drug and agrochemical metabolites, or to produce new derivatives of early-stage lead compounds with improved properties. Hypha Discovery’s panel of wild-type bacteria is highly effective in producing oxidized metabolites by whole-cell biotransformation but has l...
1 Jun 2014 to 31 Aug 2015
The major healthcare imperatives are to deliver effective prevention and treatment of diseases. Whist pharmaceutical intervention of disease progress is effective in many cases, the use of medicines can also lead to adverse reactions resulting in the need for further medical intervention, compounding the cost of therapy. The aim of this project is to furt...
1 Nov 2012 to 30 Sep 2013
The major imperative of the pharmaceutical industry is to effectively translate insights gained from basic research into new medicines. This task is toughest for brain disorders such as Parkinson’s and Alzheimer’s disease. The WHO has indicated that this will become the major medical need of the 21st century. Brain drugs take longer to get to market and t...
